Jump to content
Comments are closed. Still search and read. Click this red line for lots of support - phone numbers for prostate cancer nurses, psychologist, an advanced man, local groups, depression support, several online and Facebook groups, videos. (JimJimJimJim.com)

SINGLE DOSE OF LUTETIUM FOR mCRPC SAFETY ASSESSMENT

Barree

By Barree
in Articles on other sites

Recommended Posts

Barree Newbie

Barree

Posted
Posted

There have been a number of previous posts in the forums that explain the new treatment known as lutetium PSMA radionuclide therapy, or LuPSMA.

The Journal of Nuclear Medicine has a recent report about a study on the “Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer”.

The objective of this study was to analyze the safety and efficacy of lutetium PSMA radionuclide therapy.

The study was a multi-centre study conducted in Germany.

Initial results indicate that treatment with Lu‑PSMA is safe and seems to have low early side-effect profile.  A relevant PSA decline was detected in 70 % of patients.

Click here to read the report of this study.

 

Peter MacCallum Cancer Centre is planning a further clinical trial with Lu-PSMA in 2017.

 

Link to comment
Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing
×
×
  • Create New...